Listen
XULTOPHY (insulin degludec/liraglutide), antidiabetic
DIABETOLOGY - New medicinal product
Opinions on drugs -
Posted on
Apr 15 2016
Reason for request
Inclusion
No clinical benefit demonstrated in type 2 diabetics whose treatment is optimised with metformin + basal insulin + liraglutide in free combination
- XULTOPHY has Marketing Authorisation in the treatment of adults with type 2 diabetes to improve glycaemic control in combination with oral antidiabetics when these, alone or combined with a basal insulin, do not provide adequate glycaemic control.
- The data do not show its contribution or its benefit compared with a multi-injection insulin regimen in the context of intensifying a basal insulin treatment.
Clinical Benefit
| Substantial |
- |
Clinical Added Value
| no clinical added value |
- |
Therapeutic use
- |
English version
Contact Us
Évaluation des médicaments
